Blood Thinner Drugs Reduce COVID-19 Hospitalization & Mortality Based on Latest University of Minnesota & Collaborators

As recent research sponsored by the National Institutes of Health (NIH) indicates, COVID-19 patients at times can succumb to abnormal blood clots triggered by intense inflammation—raising the risk of severe illness and death.  Recently a trio of academic medical centers sought out to verify this hypothesis. A study led by University of Minnesota with collaborators at Mayo Clinic and University of Basel, Switzerland researchers, conducted a prospective cohort study centering on subjects 18 years of age and up diagnosed with COVID-19 between March 4th to August 27th, 2020. Involving 12 hospitals and 60 clinics of M Health Fairview system (USA). The study team investigate linkages between A) 90-day anticoagulation therapy among outpatients before COVID-19 diagnosis and the risk for hospitalization and mortality and B) inpatient anticoagulation therapy and mortality risk. Led by Sameh Hozayen, MD, MSC, assistant professor of Medicine at the University of Minnesota Medical School, the study team sought to test whether anticoagulant drugs used to inhibit blood clots who previously struggled with clots in the lungs or legs benefitted from use during the earlier part of the pandemic. Anti...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee